See more : Havells India Limited (HAVELLS.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Kraig Biocraft Laboratories, Inc. (KBLB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kraig Biocraft Laboratories, Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- Lassonde Industries Inc. (LSDAF) Income Statement Analysis – Financial Results
- Canggang Railway Limited (2169.HK) Income Statement Analysis – Financial Results
- Archer Exploration Corp. (RCHR.CN) Income Statement Analysis – Financial Results
- AlphaVest Acquisition Corp Unit (ATMVU) Income Statement Analysis – Financial Results
- Jiangxi Copper Company Limited (600362.SS) Income Statement Analysis – Financial Results
Kraig Biocraft Laboratories, Inc. (KBLB)
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. engages in developing protein-based fibers using recombinant DNA technology for commercial applications in the technical textile and specialty fiber industries in the United States. The company's products are used in military and police applications for ballistic protection; industrial applications, including critical cables and abrasion/impact resistant components; safety equipment; and composite materials for the aero-space industry. Its products are also used in various markets, such as medical textiles, geotextiles, defense and military textiles, safe and protective clothing, filtration textiles, composites with textile structure, and functional and sportive textiles, as well as textiles used in buildings and transportation. The company was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 401.62K | 97.32K | 31.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 27.62K | 28.10K | 3.68B | 13.09B | 14.79B | 11.52B | 10.56B | 16.97K | 15.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -27.62K | -28.10K | -3.68B | -13.09B | -14.79B | -11.52B | -10.56B | 14.88K | -15.42K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -2,868,283.05% | -10,850,924.48% | 46.72% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 237.87K | 176.43K | 197.75K | 88.47K | 223.05K | 148.07K | 258.89K | 397.14K | 432.01K | 439.54K | 489.43K | 465.29K | 250.60K | 141.31K | 69.80K | 33.08K | 177.02K | 164.91K |
| General & Administrative | 1.58M | 1.94M | 2.56M | 4.45M | 2.40M | 1.21M | 1.99M | 2.58M | 1.62M | 1.39M | 1.79M | 695.11K | 1.05M | 1.05M | 427.51K | 320.00K | 300.00K | 370.00K |
| Selling & Marketing | 797.41K | 0.00 | 0.00 | 0.00 | 0.00 | -2.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -7.01K | -13.34K | -5.25K |
| SG&A | 2.38M | 1.94M | 2.56M | 4.45M | 2.40M | 1.21M | 1.99M | 2.58M | 1.62M | 1.39M | 1.79M | 695.11K | 1.05M | 1.05M | 427.51K | 312.99K | 286.66K | 364.75K |
| Other Expenses | 0.00 | 779.74B | 734.43B | 516.33B | 627.20B | -1.00 | 2.00 | -4.00 | -2.00 | -4.00 | -5.19M | 3.00K | 598.00 | 93.91K | 27.20K | 12.65K | 6.21K | -5.09K |
| Operating Expenses | 2.61M | 2.12M | 2.76M | 4.53M | 2.62M | 1.36M | 2.25M | 2.98M | 2.05M | 1.83M | 2.28M | 1.16M | 1.30M | 1.29M | 524.71K | 355.65K | 472.86K | 529.67K |
| Cost & Expenses | 2.61M | 2.12M | 2.76M | 4.53M | 2.62M | 1.36M | 2.25M | 2.98M | 2.05M | 1.83M | 2.28M | 1.16M | 1.30M | 1.29M | 524.71K | 355.65K | 472.86K | 529.67K |
| Interest Income | 0.00 | 1.72K | 5.36K | 386.62 | 6.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 47.00 | 192.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 375.10K | 609.13K | 660.42K | 386.62K | 294.35K | 228.95K | 177.11K | 139.43K | 101.55K | 69.28K | 0.00 | 45.71K | 0.00 | 52.38K | 41.81K | 7.24K | 122.00 | 654.00 |
| Depreciation & Amortization | 27.62K | 28.10K | 26.14K | 28.07K | 30.78K | 26.63K | 20.29K | 16.97K | 15.42K | 7.16K | 5.89K | 5.58K | 5.37K | 453.00 | 27.40K | -2.78K | 0.00 | 0.00 |
| EBITDA | -2.59M | -2.09M | -2.73M | -4.56M | -2.58M | -913.39K | -2.14M | -2.92M | -2.04M | -1.83M | -2.22M | -1.55M | -1.29M | -1.64M | -2.72M | -355.65K | -472.86K | -529.67K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -232.39% | -2,194.56% | -9,192.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -2.61M | -2.12M | -2.76M | -4.53M | -2.62M | -959.95K | -2.16M | -2.95M | -2.05M | -1.83M | -2.28M | -1.16M | -1.30M | -1.29M | -524.71K | -355.65K | -472.86K | -529.67K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -239.02% | -2,215.41% | -9,246.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -414.99K | -1.72M | -5.29M | -437.13K | -287.98K | -209.03K | -177.11K | -128.24K | -79.25K | -38.63K | -5.25M | -1.60M | 2.10K | -589.06K | -907.38K | -4.46K | -122.00 | -333.00 |
| Income Before Tax | -3.03M | -3.84M | -8.05M | -4.97M | -2.91M | -1.17M | -2.33M | -3.07M | -2.13M | -1.87M | -7.47M | -1.20M | -1.30M | -1.78M | -2.79M | -360.10K | -472.99K | -530.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -291.07% | -2,397.40% | -9,648.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.72M | 660.42K | 386.62K | 294.35K | 19.92K | 0.00 | 139.43K | 101.55K | 69.28K | 0.00 | 48.71K | 0.00 | 52.38K | 41.81K | 7.24K | 0.00 | 321.00 |
| Net Income | -3.03M | -5.56M | -8.71M | -5.36M | -3.20M | -1.17M | -2.33M | -3.07M | -2.13M | -1.87M | -7.47M | -1.20M | -1.30M | -1.78M | -2.79M | -360.10K | -472.99K | -530.32K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -291.07% | -2,397.40% | -9,648.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 1.03B | 974.31M | 877.61M | 848.65M | 835.59M | 816.87M | 791.39M | 744.28M | 685.84M | 662.49M | 616.31M | 596.14M | 572.71M | 401.59M | 504.12M | 499.73M | 411.63M | 329.50M |
| Weighted Avg Shares Out (Dil) | 1.03B | 974.31M | 877.61M | 848.65M | 835.59M | 816.87M | 791.39M | 744.28M | 685.84M | 662.49M | 616.31M | 596.14M | 572.71M | 401.59M | 504.12M | 499.73M | 411.63M | 329.50M |
Kraig Biocraft Laboratories Prepares for Second BAM-1 Hybrid Spider Silk Production Harvest
Renowned sericulture expert, Dr. Nirmal Kumar, rejoins Kraig Labs' (OTCQB:KBLB) team in Asia to complete second BAM-1 spider silk hybrids production cycle
Kraig Biocraft Laboratories Enter Rapid Growth Rearing Phase for Third Spider Silk Production Cycle
ANN ARBOR, Mich., July 29, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces that it has entered the rapid growth rearing phase for its third spider silk production cycle of the season.
Kraig Biocraft Laboratories Further Expands Spider Silk Production Levels with Launch of Third Production Cycle
ANN ARBOR, Mich., July 22, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces the launch of its third and largest production cycle of the 2024 spider silk production season.
Kraig Biocraft Laboratories Completes Phase One of its Spider Silk Production Facility Expansion
Kraig Labs (OTCQB: KBLB) completed the first phase of construction for its production facility expansion to support the Company's third production wave
Kraig Biocraft Laboratories Announces New Spider Silk Production Contract
Kraig Labs (OTCQB:KBLB) signs production agreement for its recombinant spider silk technology, building on its new spider silk production hybrids success
Kraig Biocraft Laboratories Expands Facilities to Support Spider Silk Production Growth
ANN ARBOR, Mich., July 01, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has achieved full capacity at its current production location.
Kraig Biocraft Laboratories Increases Spider Silk Production with Next Generation of Hybrid Eggs Completed
ANN ARBOR, Mich., June 25, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has expanded its production of spider silk with the creation of the next generation of BAM-1...
Kraig Biocraft Laboratories Successfully Completes Cocooning in First Commercial Production Run of BAM-1 Spider Silk Hybrids
ANN ARBOR, Mich., June 17, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that it has successfully completed cocoon production for the first commercial production run of its BAM-1 hybrids.
Kraig Biocraft Laboratories Announces Production Update for BAM-1 Spider Silk Hybrids
ANN ARBOR, Mich., June 11, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), announces today that production of its BAM-1 spider silk hybrid strain continues to set records for silkworm size, growth, and...
24/7 Market News Publishes Report on how Kraig Biocraft's BAM-1 Spider Silk Hybrid Production Affects Spider Silk Market
Denver, Colorado--(Newsfile Corp. - June 5, 2024) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, today publishes a news report on Kraig Biocraft Laboratories (OTCQB: KBLB) launching the production phase...
Source: https://incomestatements.info
Category: Stock Reports